TY  - GEN
AU  - Kato,Yuka
AU  - Ninomiya,Kiichiro
AU  - Ohashi,Kadoaki
AU  - Tomida,Shuta
AU  - Makimoto,Go
AU  - Watanabe,Hiromi
AU  - Kudo,Kenichiro
AU  - Matsumoto,Shingo
AU  - Umemura,Shigeki
AU  - Goto,Koichi
AU  - Ichihara,Eiki
AU  - Ninomiya,Takashi
AU  - Kubo,Toshio
AU  - Sato,Akiko
AU  - Hotta,Katsuyuki
AU  - Tabata,Masahiro
AU  - Toyooka,Shinichi
AU  - Maeda,Yoshinobu
AU  - Kiura,Katsuyuki
TI  - Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions
SN  - 1349-7006
PY  - 2018///1012
KW  - Anilides
KW  - pharmacology
KW  - Animals
KW  - Antigens, Differentiation, B-Lymphocyte
KW  - genetics
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Carcinoma, Non-Small-Cell Lung
KW  - drug therapy
KW  - Cell Line, Tumor
KW  - Crizotinib
KW  - Drug Resistance, Neoplasm
KW  - ErbB Receptors
KW  - metabolism
KW  - Female
KW  - Gefitinib
KW  - Heparin-binding EGF-like Growth Factor
KW  - Histocompatibility Antigens Class II
KW  - Humans
KW  - Lung Neoplasms
KW  - Mice
KW  - Mice, Inbred NOD
KW  - Oncogene Proteins, Fusion
KW  - Protein Kinase Inhibitors
KW  - Protein-Tyrosine Kinases
KW  - antagonists & inhibitors
KW  - Proto-Oncogene Proteins
KW  - Pyrazoles
KW  - Pyridines
KW  - Quinazolines
KW  - Receptor Protein-Tyrosine Kinases
KW  - Sodium-Phosphate Cotransporter Proteins, Type IIb
KW  - Up-Regulation
KW  - Xenograft Model Antitumor Assays
KW  - Axl Receptor Tyrosine Kinase
N1  - Publication Type: Journal Article
UR  - https://doi.org/10.1111/cas.13752
ER  -